On June 16, 2025, Shanghai Escugen Biotechnology and SunRock Biopharma announced a strategic alliance tojoin forces in a strategic partnership to co-develop SRB123, a First-in-Class antibody-drug conjugate (ADC) targeting C-C motif chemokine receptor 9 (CCR9).
The Collaboration has been covered by multiple media outlets:
